

Neuren (NEU) – ASX Announcement

11 February 2026

Neuren Investor Webinar on 12 February 2026

Investor Webinar | Thursday, 12 Feb 2026 at 10.30 AM AEDT

You are invited to register using this link:

https://us06web.zoom.us/webinar/register/WN_PAmRjBeJQQeUn-FItCmGAg

Participants may submit questions at registration or during the session

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) management will host an investor webinar on Thursday, 12 February 2026 at 10:30 AM Australian Eastern Daylight Time to discuss Neuren's recently announced business updates. Registration for the webinar may be completed via the link above.

About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.

DAYBUE® (trofinetide) and DAYBUE STIX (trofinetide) are approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with a Phase 3 clinical trial in Phelan-McDermid syndrome ongoing and positive results achieved in Phase 2 clinical trials in Pitt Hopkins syndrome and Angelman syndrome. Recognising the urgent unmet need, each program has been granted "orphan drug" designation in the United States and the European Union. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

Contact:

investorrelations@neurenpharma.com

Jon Pilcher, CEO: +61 438 422 271

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the Board of Neuren Pharmaceuticals Limited, Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC 3123

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.